CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS . SYDNEY, March 24, 2026 /PRNewswire/ — Celosia Therapeutics, an Australian biotech company develo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results